Loading...
Critical appraisal of cabazitaxel in the management of advanced prostate cancer
Docetaxel remains a cornerstone of therapy for the patient with metastatic castration-resistant prostate cancer (CRPC). However, the landscape of CRPC therapy is changing rapidly – recently, data from the phase III TROPIC study revealed a survival advantage with the novel taxane cabazitaxel/predniso...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2998247/ https://ncbi.nlm.nih.gov/pubmed/21152241 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CIA.S14570 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|